Direkt zum Inhalt
Merck

PHR1271

Supelco

Levodopa

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(e):

3,4-Dihydroxy-L-Phenylalanin, 3-(3,4-Dihydroxyphenyl)-L-alanin, L-3-Hydroxytyrosin, L-DOPA, Levodopa

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Lineare Formel:
(HO)2C6H3CH2CH(NH2)CO2H
CAS-Nummer:
Molekulargewicht:
197.19
Beilstein:
2215169
EG-Nummer:
MDL-Nummer:
UNSPSC-Code:
41116107
PubChem Substanz-ID:
NACRES:
NA.24

Qualität

certified reference material
pharmaceutical secondary standard

Qualitätsniveau

Agentur

traceable to BP 213
traceable to Ph. Eur. L0400000
traceable to USP 1361009

API-Familie

levodopa

Analysenzertifikat (CofA)

current certificate can be downloaded

Methode(n)

HPLC: suitable
gas chromatography (GC): suitable

mp (Schmelzpunkt)

276-278 °C (lit.)

Anwendung(en)

pharmaceutical (small molecule)

Format

neat

Lagertemp.

2-8°C

SMILES String

N[C@@H](Cc1ccc(O)c(O)c1)C(O)=O

InChI

1S/C9H11NO4/c10-6(9(13)14)3-5-1-2-7(11)8(12)4-5/h1-2,4,6,11-12H,3,10H2,(H,13,14)/t6-/m0/s1

InChIKey

WTDRDQBEARUVNC-LURJTMIESA-N

Angaben zum Gen

human ... DRD3(1814)

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards. Levodopa is a metabolic precursor of the neurotransmitter dopamine and is widely used in the treatment of Parkinson′s disease.

Anwendung

Levodopa may be used as a pharmaceutical reference standard for the quantification of the analyte in pharmaceutical formulations using flow injection spectrophotometric method and 1H nuclear magnetic resonance spectroscopy.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Hinweis zur Analyse

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Sonstige Hinweise

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Fußnote

To see an example of a Certificate of Analysis for this material enter LRAC2957 in the slot below. This is an example certificate only and may not be the lot that you receive.

Piktogramme

Exclamation mark

Signalwort

Warning

Gefahreneinstufungen

Acute Tox. 4 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Zielorgane

Respiratory system

Lagerklassenschlüssel

11 - Combustible Solids

WGK

WGK 3


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

Die passende Version wird nicht angezeigt?

Wenn Sie eine bestimmte Version benötigen, können Sie anhand der Lot- oder Chargennummer nach einem spezifischen Zertifikat suchen.

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Parkinson's Disease and Related Disorders, 506(1), 97-104 (2006)
1H nuclear magnetic resonance spectroscopy analysis for simultaneous determination of levodopa, carbidopa and methyldopa in human serum and pharmaceutical formulations
Talebpour Z, et al.
Analytica Chimica Acta, 506(1), 97-104 (2004)
Handbook of Parkinson's Disease
Parkinson's Disease and Related Disorders, 506(4), 97-104 (2007)
L H Marcolino-Júnior et al.
Journal of pharmaceutical and biomedical analysis, 25(3-4), 393-398 (2001-05-30)
A flow injection spectrophotometric procedure was developed for determining levodopa in tablets. The determination of this drug was carried out by reacting it with lead(IV) dioxide immobilized in polyester resin packed in a solid-phase reactor and the dopachrome yielded was
Roshan Cools
Neuroscience and biobehavioral reviews, 30(1), 1-23 (2005-06-07)
It is well recognised that patients with Parkinson's disease exhibit cognitive deficits, even in the earliest disease stages. Whereas, L-DOPA therapy in early Parkinson's disease is accepted to improve the motor symptoms, the effects on cognitive performance are more complex:

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.